白细胞介素17A与炎症性肠病的关系研究进展
|
摘要
炎症性肠病(inflammatory bowel disease,IBD)包括溃疡性结肠炎(ulcerative colitis,UC)和克罗恩病(Crohn’s disease,CD),是一种反复发作的慢性炎症性肠道疾病,其发病机制目前尚不十分清楚。通常认为免疫系统功能异常与IBD的发生、发展关系密切,Th17是一种T淋巴细胞亚群,成熟的Th17可以分泌IL-17A、IL-17F、IF-21、IL-22等一系列炎症因子,其中IL-17A在肠上皮黏膜损伤过程中起重要作用。随着对IL-17A研究的进一步深入,针对IL-17A分泌过程进行调节干预也成为IBD治疗的新思路。
Inflammatory bowel disease(IBD), including ulcerative colitis(UC) and Crohn's disease(CD), is a recurrent chronic intestinal inflammatory disease. Its pathogenesis is still not clear. It's generally accepted that the immune system dysfunction is related to the occurrence and development of IBD. Th17 cells are a subset of T lymphocyte. Th17 cells can secrete a series of inflammatory factors, such as IL-17A, IL-17F, IF-21, IL-22, and IL-17A plays an important role in the process of intestinal mucosal injury. With the further study of IL-17A, regulatory intervention for the IL-17A secretory process may be a new approach to the treatment of IBD.
Inflammatory bowel disease(IBD), including ulcerative colitis(UC) and Crohn's disease(CD), is a recurrent chronic intestinal inflammatory disease. Its pathogenesis is still not clear. It's generally accepted that the immune system dysfunction is related to the occurrence and development of IBD. Th17 cells are a subset of T lymphocyte. Th17 cells can secrete a series of inflammatory factors, such as IL-17A, IL-17F, IF-21, IL-22, and IL-17A plays an important role in the process of intestinal mucosal injury. With the further study of IL-17A, regulatory intervention for the IL-17A secretory process may be a new approach to the treatment of IBD.
引文
[1] 尚瑞,吴军,郑雪皎,等.外周血Th17、Treg细胞水平在溃疡性结肠炎和克罗恩病中的比较研究[J].胃肠病学和肝病学杂志,2017,26(5):559-561.DOI:10.3969/j.issn.1006-5709.2017.05.021.SHANG R,WU J,ZHENG X J,et al.A comparative study of the peripheral blood Th17 and Treg cells in Crohn’s disease and ulcerative colitis [J].Chin J Gastroenterol Hepatol,2017,26(5):559-561.DOI:10.3969/j.issn.1006-5709.2017.05.021.
[2] CUA D J,TATO C M.Innate IL-17-producing cells:the sentinels of the immune system [J].Nat Rev Immunol,2010,10(7):479-489.DOI:10.1038/nri2800.
[3] RUDRA D,DEROOS P,CHAUDHRY A,et al.Transcription factor Foxp3 and its protein partners form a complex regulatory network [J].Nat Immunol,2012,13(10):1010-1019.DOI:10.1038/ni.2402.
[4] WU C,YOSEF N,THALHAMER T,et al.Induction of pathogenic TH17 cells by inducible salt-sensing kinase SGK1 [J].Nature,2013,496(7446):513-517.DOI:10.1038/nature11984.
[5] O’CONNELL R M,KAHN D,GIBSON W S,et al.MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development [J].Immunity,2010,33(4):607-619.DOI:10.1016/j.immuni.2010.09.009.
[6] LI L,RUAN Q,HILLIARD B,et al.Transcriptional regulation of the Th17 immune response by IKK (alpha) [J].J Exp Med,2011,208(4):787-796.DOI:10.1084/jem.20091346.
[7] MCKENZIE A N,SPITS H,EBERL G.Innate lymphoid cells in inflammation and immunity [J].Immunity,2014,41(3):366-374.DOI:10.1016/j.immuni.2014.09.006.
[8] GAFFEN S L,JAIN R,GARG A V,et al.The IL-23-IL-17 immune axis:from mechanisms to therapeutic testing [J].Nat Rev Immunol,2014,14(9):585.DOI:10.1038/nri3707.
[9] MONIN L,GAFFEN S L.Interleukin 17 family cytokines:signaling mechanisms,biological activities,and therapeutic implications [J].Cold Spring Harb Perspect Biol,2018,10(4).pii:a028522.DOI:10.1101/cshperspect.a028522.
[10] YOSEF N,SHALEK A K,GAUBLOMME J T,et al.Dynamic regulatory network controlling Th17 cell differentiation [J].Nature,2013,496(7446):461-468.DOI:10.1038/nature11981.
[11] QU F,GAO H,ZHU S,et al.TRAF6-dependent Act1 phosphorylation by the IκB kinase-related kinases suppresses interleukin-17-induced NF-κB activation [J].Mol Cell Biol,2012,32(19):3925-3937.DOI:10.1128/MCB.00268-12.
[12] ZHU S,PAN W,SONG X,et al.The microRNA miR-23b suppresses IL-17-associated autoimmune inflammation by targeting TAB2,TAB3 and IKK-α [J].Nat Med,2012,18(7):1077-1086.DOI:10.1038/nm.2815.
[13] XIAO Y,JIN J,CHANG M,et al.TPL2 mediates autoimmune inflammation through activation of the TAK1 axis of IL-17 signaling [J].J Exp Med,2014,211(8):1689-1702.DOI:10.1084/jem.20132640.
[14] 王静静,宋昕阳,钱友存.白介素-17 A与白介素-17 C在炎症性疾病中的研究进展[J].中国免疫学杂志,2015,31(11):1441-1445,1452.DOI:10.3969/j.issn.1000-484X.2015.11.001.
[15] ZHONG B,LIU X,WANG X,et al.Negative regulation of IL-17-mediated signaling and inflammation by the ubiquitin-specific protease USP25 [J].Nat Immunol,2012,13(11):1110-1117.DOI:10.1038/ni.2427.
[16] SONG X,QIAN Y.IL-17 family cytokines mediated signaling in the pathogenesis of inflammatory diseases [J].Cell Signal,2013,25(12):2335-2347.DOI:10.1016/j.cellsig.2013.07.021.
[17] 李为慧,吴正祥.Th17细胞及IL-23在炎症性肠病中的研究进展[J].胃肠病学和肝病学杂志,2012,21(2):118-122.DOI:10.3969/j.issn.1006-5709.2012.02.006.LI W H,WU Z X.The progress in the study of Th17 cells and IL-23 in inflammatory bowel disease [J].Chin J Gastroenterol Hepatol,2012,21(2):118-122.DOI:10.3969/j.issn.1006-5709.2012 .02.006.
[18] MONTELEONE I,PALLONE F,MONTELEONE G,et al.Th17-related cytokines:new players in the control of chronic intestinal inflammation [J].BMC Med,2011,9:122.DOI:10.1186/1741-7015-9-122.
[19] BRAZIL J C,LOUIS N A,PARKOS C A.The role of polymorphonuclear leukocyte trafficking in the perpetuation of inflammation during inflammatory bowel disease [J].Inflamm Bowel Dis,2013,19(7):1556-1565.DOI:10.1097/mib.0b013e318281f54e.
[20] CAO A T,YAO S,GONG B,et al.Th17 cells upregulate polymeric Ig receptor and intestinal IgA and contribute to intestinal homeostasis [J].J Immunol,2012,189(9):4666-4673.DOI:10.4049/jimmunol.1200955.
[21] TANI S,TAKANO R,TAMURA S,et al.Digoxin attenuates murine experimental colitis by downregulating Th17-related cytokines [J].Inflamm Bowel Dis,2017,23(5):728-738.DOI:10.1097/MIB.0000000000001096.
[22] WEDEBYE SCHMIDT E G,LARSEN H L,KRISTENSEN N N,et al.TH17 cell induction and effects of IL-17A and IL-17F blockade in experimental colitis [J].Inflamm Bowel Dis,2013,19(8):1567-1576.DOI:10.1097/mib.0b013e318286fa1c.
[23] 朱超慧.中和IL-17及受体对DSS诱导小鼠结肠炎的作用[D].北京:中国人民解放军医学院,2016.
[24] HUEBER W,SANDS B E,LEWITZKY S,et al.Secukinumab,a human anti-IL-17A monoclonal antibody,for moderate to severe Crohn’s disease:unexpected results of a randomised,double-blind placebo-controlled trial [J].Gut,2012,61(12):1693-1700.DOI:10.1136/gutjnl-2011-301668.
[25] OHMAN L,DAHLéN R,ISAKSSON S,et al.Serum IL-17A in newly diagnosed treatment-naive patients with ulcerative colitis reflects clinical disease severity and predicts the course of disease [J].Inflamm Bowel Dis,2013,19(11):2433-2439.DOI:10.1097/MIB.0b013e3182a563cb.
[26] KANAI T,MIKAMI Y,SUJINO T,et al.RORγt-dependent IL-17A-producing cells in the pathogenesis of intestinal inflammation [J].Mucosal Immunol,2012,5(3):240-247.DOI:10.1038/mi.2012.6.
[27] SO A Y,ZHAO J L,BALTIMORE D.The Yin and Yang of microRNAs:leukemia and immunity [J].Immunol Rev,2013,253(1):129-145.DOI:10.1111/imr.12043.
[28] SANDBOM W J,GASINK C,GAO L L,et al.Ustekinumab induction and maintenance therapy in refractory Crohn's disease [J].N Engl J Med,2012,367(16):1519-1528.DOI:10.1056/NEJMoa1203572.
[2] CUA D J,TATO C M.Innate IL-17-producing cells:the sentinels of the immune system [J].Nat Rev Immunol,2010,10(7):479-489.DOI:10.1038/nri2800.
[3] RUDRA D,DEROOS P,CHAUDHRY A,et al.Transcription factor Foxp3 and its protein partners form a complex regulatory network [J].Nat Immunol,2012,13(10):1010-1019.DOI:10.1038/ni.2402.
[4] WU C,YOSEF N,THALHAMER T,et al.Induction of pathogenic TH17 cells by inducible salt-sensing kinase SGK1 [J].Nature,2013,496(7446):513-517.DOI:10.1038/nature11984.
[5] O’CONNELL R M,KAHN D,GIBSON W S,et al.MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development [J].Immunity,2010,33(4):607-619.DOI:10.1016/j.immuni.2010.09.009.
[6] LI L,RUAN Q,HILLIARD B,et al.Transcriptional regulation of the Th17 immune response by IKK (alpha) [J].J Exp Med,2011,208(4):787-796.DOI:10.1084/jem.20091346.
[7] MCKENZIE A N,SPITS H,EBERL G.Innate lymphoid cells in inflammation and immunity [J].Immunity,2014,41(3):366-374.DOI:10.1016/j.immuni.2014.09.006.
[8] GAFFEN S L,JAIN R,GARG A V,et al.The IL-23-IL-17 immune axis:from mechanisms to therapeutic testing [J].Nat Rev Immunol,2014,14(9):585.DOI:10.1038/nri3707.
[9] MONIN L,GAFFEN S L.Interleukin 17 family cytokines:signaling mechanisms,biological activities,and therapeutic implications [J].Cold Spring Harb Perspect Biol,2018,10(4).pii:a028522.DOI:10.1101/cshperspect.a028522.
[10] YOSEF N,SHALEK A K,GAUBLOMME J T,et al.Dynamic regulatory network controlling Th17 cell differentiation [J].Nature,2013,496(7446):461-468.DOI:10.1038/nature11981.
[11] QU F,GAO H,ZHU S,et al.TRAF6-dependent Act1 phosphorylation by the IκB kinase-related kinases suppresses interleukin-17-induced NF-κB activation [J].Mol Cell Biol,2012,32(19):3925-3937.DOI:10.1128/MCB.00268-12.
[12] ZHU S,PAN W,SONG X,et al.The microRNA miR-23b suppresses IL-17-associated autoimmune inflammation by targeting TAB2,TAB3 and IKK-α [J].Nat Med,2012,18(7):1077-1086.DOI:10.1038/nm.2815.
[13] XIAO Y,JIN J,CHANG M,et al.TPL2 mediates autoimmune inflammation through activation of the TAK1 axis of IL-17 signaling [J].J Exp Med,2014,211(8):1689-1702.DOI:10.1084/jem.20132640.
[14] 王静静,宋昕阳,钱友存.白介素-17 A与白介素-17 C在炎症性疾病中的研究进展[J].中国免疫学杂志,2015,31(11):1441-1445,1452.DOI:10.3969/j.issn.1000-484X.2015.11.001.
[15] ZHONG B,LIU X,WANG X,et al.Negative regulation of IL-17-mediated signaling and inflammation by the ubiquitin-specific protease USP25 [J].Nat Immunol,2012,13(11):1110-1117.DOI:10.1038/ni.2427.
[16] SONG X,QIAN Y.IL-17 family cytokines mediated signaling in the pathogenesis of inflammatory diseases [J].Cell Signal,2013,25(12):2335-2347.DOI:10.1016/j.cellsig.2013.07.021.
[17] 李为慧,吴正祥.Th17细胞及IL-23在炎症性肠病中的研究进展[J].胃肠病学和肝病学杂志,2012,21(2):118-122.DOI:10.3969/j.issn.1006-5709.2012.02.006.LI W H,WU Z X.The progress in the study of Th17 cells and IL-23 in inflammatory bowel disease [J].Chin J Gastroenterol Hepatol,2012,21(2):118-122.DOI:10.3969/j.issn.1006-5709.2012 .02.006.
[18] MONTELEONE I,PALLONE F,MONTELEONE G,et al.Th17-related cytokines:new players in the control of chronic intestinal inflammation [J].BMC Med,2011,9:122.DOI:10.1186/1741-7015-9-122.
[19] BRAZIL J C,LOUIS N A,PARKOS C A.The role of polymorphonuclear leukocyte trafficking in the perpetuation of inflammation during inflammatory bowel disease [J].Inflamm Bowel Dis,2013,19(7):1556-1565.DOI:10.1097/mib.0b013e318281f54e.
[20] CAO A T,YAO S,GONG B,et al.Th17 cells upregulate polymeric Ig receptor and intestinal IgA and contribute to intestinal homeostasis [J].J Immunol,2012,189(9):4666-4673.DOI:10.4049/jimmunol.1200955.
[21] TANI S,TAKANO R,TAMURA S,et al.Digoxin attenuates murine experimental colitis by downregulating Th17-related cytokines [J].Inflamm Bowel Dis,2017,23(5):728-738.DOI:10.1097/MIB.0000000000001096.
[22] WEDEBYE SCHMIDT E G,LARSEN H L,KRISTENSEN N N,et al.TH17 cell induction and effects of IL-17A and IL-17F blockade in experimental colitis [J].Inflamm Bowel Dis,2013,19(8):1567-1576.DOI:10.1097/mib.0b013e318286fa1c.
[23] 朱超慧.中和IL-17及受体对DSS诱导小鼠结肠炎的作用[D].北京:中国人民解放军医学院,2016.
[24] HUEBER W,SANDS B E,LEWITZKY S,et al.Secukinumab,a human anti-IL-17A monoclonal antibody,for moderate to severe Crohn’s disease:unexpected results of a randomised,double-blind placebo-controlled trial [J].Gut,2012,61(12):1693-1700.DOI:10.1136/gutjnl-2011-301668.
[25] OHMAN L,DAHLéN R,ISAKSSON S,et al.Serum IL-17A in newly diagnosed treatment-naive patients with ulcerative colitis reflects clinical disease severity and predicts the course of disease [J].Inflamm Bowel Dis,2013,19(11):2433-2439.DOI:10.1097/MIB.0b013e3182a563cb.
[26] KANAI T,MIKAMI Y,SUJINO T,et al.RORγt-dependent IL-17A-producing cells in the pathogenesis of intestinal inflammation [J].Mucosal Immunol,2012,5(3):240-247.DOI:10.1038/mi.2012.6.
[27] SO A Y,ZHAO J L,BALTIMORE D.The Yin and Yang of microRNAs:leukemia and immunity [J].Immunol Rev,2013,253(1):129-145.DOI:10.1111/imr.12043.
[28] SANDBOM W J,GASINK C,GAO L L,et al.Ustekinumab induction and maintenance therapy in refractory Crohn's disease [J].N Engl J Med,2012,367(16):1519-1528.DOI:10.1056/NEJMoa1203572.